Gilead Sciences Inc (GILD)
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
📈 **POSITIVE** • Medium confidence analysis (79%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business